188 related articles for article (PubMed ID: 14716708)
1. Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study.
Pae CU; Kim YJ; Won WY; Kim HJ; Lee S; Lee CU; Lee SJ; Kim DW; Lee C; Min WS; Kim CC; Paik IH; Serretti A
Hum Psychopharmacol; 2004 Jan; 19(1):25-9. PubMed ID: 14716708
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
[TBL] [Abstract][Full Text] [Related]
4. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
Baldwin D; Bridgman K; Buis C
J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
6. An open-label, flexible-dose study of memantine in major depressive disorder.
Ferguson JM; Shingleton RN
Clin Neuropharmacol; 2007; 30(3):136-44. PubMed ID: 17545748
[TBL] [Abstract][Full Text] [Related]
7. Paroxetine in depressed adolescents with intellectual disability: an open label study.
Masi G; Marcheschi M; Pfanner P
J Intellect Disabil Res; 1997 Jun; 41 ( Pt 3)():268-72. PubMed ID: 9219077
[TBL] [Abstract][Full Text] [Related]
8. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
Chokka P; Legault M
Depress Anxiety; 2008; 25(12):E173-81. PubMed ID: 19006260
[TBL] [Abstract][Full Text] [Related]
9. An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder.
Pinto C; Trivedi JK; Vankar GK; Sharma PS; Narasimha V
J Indian Med Assoc; 2007 Jul; 105(7):364, 366, 368 passim. PubMed ID: 18178988
[TBL] [Abstract][Full Text] [Related]
10. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
11. [Comparative study of paroxetine and mianserin in depression in elderly patients: efficacy, tolerance, serotonin dependence].
Daléry J; Aubin V
Encephale; 2001; 27(1):71-81. PubMed ID: 11294041
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study.
Anghelescu IG; Kohnen R; Szegedi A; Klement S; Kieser M
Pharmacopsychiatry; 2006 Nov; 39(6):213-9. PubMed ID: 17124643
[TBL] [Abstract][Full Text] [Related]
14. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
[TBL] [Abstract][Full Text] [Related]
15. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression.
Baldwin DS; Hawley CJ; Abed RT; Maragakis BP; Cox J; Buckingham SA; Pover GH; Ascher A
J Clin Psychiatry; 1996; 57 Suppl 2():46-52. PubMed ID: 8626363
[TBL] [Abstract][Full Text] [Related]
16. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
Chauvet-Gélinier JC
Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
[TBL] [Abstract][Full Text] [Related]
19. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety.
Olié JP; Tonnoir B; Ménard F; Galinowski A
Depress Anxiety; 2007; 24(5):318-24. PubMed ID: 17041922
[TBL] [Abstract][Full Text] [Related]
20. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression.
Malhi GS; Ng F; Berk M
Aust N Z J Psychiatry; 2008 Apr; 42(4):346-9. PubMed ID: 18330778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
